CRISPR Therapeutics AG — Director's Dealing 2016

Oct 18, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: Novak Rodger (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	1215005	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$1.81	2025-09-10	Common Shares (268093)		Direct

Footnotes

F1: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31equal monthly installments thereafter.